Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases

NCT04299646 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT04299646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04299646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Lead sponsor
Centre Francois Baclesse
Phase
Phase 2
Overall status
Recruiting
Start date
July 1, 2020
Completion date
August 31, 2029
Enrollment
77 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma, radiotherapy